- Net assets per share 6.24 pence at 31 March 2021 (2020: 2.50 pence). - Profit after tax of £3.09 million (2020: loss £0.30 million). - Investments at 31 March 2021 valued at £5.11 million (2020: £1.18 million). - Spend on new investments of £1.90 million (2020: £1.38 million). - Investment realisation proceeds of £1.21 million (2020: £2.03 million). - Cash at 31 March 2021 of £0.05 million (2020: £0.90 million). - Post year end raised gross cash proceeds of £4.11 million under a placing and open offer in April 2021. - No part of the £3.00 million shareholder loan facility drawn down to date. Whilst the arrival of a number of Covid-19 vaccines and the associated roll-out of the global vaccination programs should now provide a pathway for the gradual easing of th
Global Microbiome Markets Report 2021-2030: Growing Technological Improvements Trends Gaining Popularity prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
4D pharma encouraged after additional analysis of IBS drug data
Presented as a poster at the medical and scientific conference, Digestive Disease Week, the new analysis builds on the top-line results released last October
4D pharma PLC (LON:DDDD, NASDAQ:LBPS) said it has provided a more detailed analysis of its Live Biotherapeutic, Blautix, which is both significant and supportive of its continued development as an irritable bowel syndrome treatment.
The data, presented as a poster at the medical and scientific conference Digestive Disease Week, builds on the top-line results released last October.
The poster revealed “strong and statistically significant activity” on the key symptom of bowel habit, which 4D describes as a “potential approvable primary endpoint per regulatory guidelines”.
About 4D pharma plc 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism. 4D pharma s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programmes, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospi